Table 2 Clinicopathological characteristics statistics of patients from GSE13507
Clinicopathological Features | CDCA3 expression level | Total | P value | |
|---|---|---|---|---|
Low | High | |||
Overall | 90 | 75 | 165 | Â |
Gender | Â | Â | Â | |
 Female | 15 (16.67%) | 15 (20.00%) | 30 | 0.5804 |
 Male | 75 (83.33%) | 60 (80.00%) | 135 | |
Grade | Â | Â | Â | Â |
 Low | 76 (84.44%) | 29 (38.67%) | 105 | < 0.001*** |
 High | 14 (15.56%) | 46 (62.33%) | 60 | |
Invasiveness | Â | Â | Â | Â |
 Muscle invasive | 22 (22.44%) | 40 (53.33%) | 62 | < 0.001*** |
 Non-muscle invasive | 68 (77.56%) | 35 (46.67%) | 103 | |
M stage | Â | Â | Â | Â |
 M0 | 86 (95.56%) | 72 (96.00%) | 158 | 0.8878 |
 M1 + MX | 4 (4.44%) | 3 (4.00%) | 7 | |
N stage | Â | Â | Â | Â |
 N0 | 86 (95.56%) | 63 (84.00%) | 149 | 0.0125* |
 N1 + N2 + N3 + NX | 4 (4.44%) | 12 (16.00%) | 16 | |
Recurrence | Â | Â | Â | Â |
 Yes | 22 (24.44%) | 14 (18.67%) | 36 | 0.3709 |
 No | 68 (75.56%) | 61 (81.33%) | 129 |  |
Progression | Â | Â | Â | Â |
 Yes | 11 (12.22%) | 20 (26.67%) | 31 | 0.0180* |
 No | 79 (87.78%) | 55 (73.33%) | 134 |  |